MedTrace Logo

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

NCT05530421 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-02-23

No results posted yet for this study

Summary

The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

Conditions

  • Relapsed and Refractory Multiple Myeloma

Interventions

DRUG

Selinexor

Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.

DRUG

Venetoclax

Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.

DRUG

Dexamethasone

Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.

Sponsors & Collaborators

  • Karyopharm Therapeutics Inc

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Dickran Kazandjian, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-26
Primary Completion
2028-03-26
Completion
2030-03-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05530421 on ClinicalTrials.gov